about
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvantToll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responsesSystems biology applied to vaccine and immunotherapy developmentCurrent advancements and potential strategies in the development of MERS-CoV vaccinesRationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvantsProtective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite proteinUnlipidated outer membrane protein Omp16 (U-Omp16) from Brucella spp. as nasal adjuvant induces a Th1 immune response and modulates the Th2 allergic response to cow's milk proteinsVaccines: the Fourth CenturyRecent advances of vaccine adjuvants for infectious diseasesCarbon nanotubes as vaccine scaffoldsToward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptorsA novel laser vaccine adjuvant increases the motility of antigen presenting cellsEnhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE)C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c miceDNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvantVault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of miceClinical vaccine development for H5N1 influenza.Technological Microbiology: Development and ApplicationsProspects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.Protective immunity to influenza: lessons from the virus for successful vaccine design.Inactivated influenza vaccines: recent progress and implications for the elderly.Laser vaccine adjuvants. History, progress, and potentialControlling the HIV/AIDS epidemic: current status and global challengesAdjuvant solution for pandemic influenza vaccine productionIdentification of Molecular Signatures from Different Vaccine Adjuvants in Chicken by Integrative Analysis of Microarray Data.Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.Immunogenomics and systems biology of vaccines.Novel vaccines to human rabiesImmunological mechanisms underlying protection mediated by RTS,S: a review of the available data.Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in miceComparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.The Use of Xanthan Gum as Vaccine Adjuvant: An Evaluation of Immunostimulatory Potential in BALB/c Mice and Cytotoxicity In Vitro.Chemical synthesis and proinflammatory responses of monophosphoryl lipid A adjuvant candidates.An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice.Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics.Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.Host immunity in the protective response to nasal immunization with a pneumococcal antigen associated to live and heat-killed Lactobacillus casei.Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.Laser vaccine adjuvant for cutaneous immunization.
P2860
Q21091066-EC549E1D-10A8-43D2-8838-F5F2FAE746D3Q24624348-A7E51F67-858A-495C-9D6F-6575F645A382Q26830374-C5CF8131-2FDE-463F-A71B-9E5DE6706640Q27012578-C3570C1C-9FDC-4C68-849F-27215F0C6ACFQ27025822-4B0108A8-9528-40D6-A828-0C7C68F41374Q27310086-55F28B08-DF4A-4BFF-8069-926E3C29BA73Q27311087-B20B45EE-CF85-4648-997A-7C4C9E4C7135Q27490454-A9FC0747-47E8-4C60-8544-D3C3262A2BDBQ28083679-E383D207-1526-4F09-A07F-63AB5393C0FCQ28392532-4D88576C-398E-4D9B-9F32-AEE5C510B8C5Q28472202-03B6A163-221F-4DB6-9592-0AF3ED7600D5Q28475973-943F9327-CC56-4407-A068-92F97CB51517Q28476101-BA20C091-26CE-4D09-A4B9-91750EF04FFDQ28478982-AE9D0C42-FF91-47A3-A1AE-86980220CBD6Q28542668-E3F5A78B-B61C-461D-A6C4-4D85C6C3A658Q28727249-0C203A27-E949-46CD-9676-BCC8BDB66484Q30222083-3103A072-0A93-454B-BE26-EAB5742B7835Q30250972-7F7BD2D0-65E0-4BDA-B571-C91760400C2AQ30375714-AE4C4AF6-3D42-418F-874E-25FC641613A7Q30377729-7EAE92B7-C8BE-4F67-83E6-5F3A7541B581Q30399057-5654A4F3-0C2D-48E9-BC61-4CBF9AFB5980Q30413501-0446F797-9C52-4CDC-BBB1-8A00E0FF1991Q30420558-5FDC9BB8-C258-4227-AA77-E78805770817Q30422038-698D57F5-719C-48B9-B171-474ADE16927EQ31054454-50B78AC9-14EE-4AF7-A667-5770595F5992Q31076192-8BCFCF74-57BE-4D1B-AD53-4CA7350CE37CQ33350387-8F0AE3CC-9BA7-492A-B8C7-004EA7CB8AABQ33507253-AA7114F7-C747-467C-A18B-038864A41078Q33521372-F0B27C09-5807-4E89-9C6E-EB56C5B649CAQ33594345-BA717B48-BC01-4D47-8A19-4BE1D89672B8Q33615236-EE515FC9-4D4B-4D96-BE0F-0F1BC5EEE0A8Q33703757-2718C970-3682-4664-B8BA-969378B221CBQ33710401-8CCA7595-7B15-4C33-A753-B99C3F8511ECQ33714195-77A8EC6A-0C81-4D4E-8BD3-37280A7414A9Q33802696-4C9EF18B-6930-4588-9B5F-BFD7F7F3F029Q33805176-906294D5-96CB-49D3-89E4-E15C6D57503CQ33956199-71F19F1A-B4F5-40ED-9F38-8C582F26F92DQ33990842-DDCFD746-9270-4331-BD28-846F952B3A71Q34033764-3DA964D9-5444-46E8-82D8-13D745A07B5EQ34046148-BC660070-6188-410D-8C70-A5F1C0AE3396
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New horizons in adjuvants for vaccine development.
@en
New horizons in adjuvants for vaccine development.
@nl
type
label
New horizons in adjuvants for vaccine development.
@en
New horizons in adjuvants for vaccine development.
@nl
prefLabel
New horizons in adjuvants for vaccine development.
@en
New horizons in adjuvants for vaccine development.
@nl
P2093
P356
P1433
P1476
New horizons in adjuvants for vaccine development.
@en
P2093
Martin Friede
Rhea N Coler
Sylvie Bertholet
P356
10.1016/J.IT.2008.09.006
P577
2008-12-06T00:00:00Z